Randy Ramseyer

Randy Ramseyer was a career federal prosecutor in the Abingdon office whose work with Rick Mountcastle helped turn a vast documentary record into a federal criminal case against Purdue Pharma. The prosecution did not have to prove that the company’s misbranding caused particular overdoses or cases of addiction; it had to establish that Purdue had criminally misbranded OxyContin. That narrower legal path made Ramseyer’s patient, technical approach consequential: a case that the company apparently underestimated as a small-town effort ultimately brought its corporate officers into court to accept responsibility for their role in the crime.

Identity and Professional Setting

Ramseyer worked from the federal government’s satellite office in Abingdon, three hours west of U.S. Attorney John Brownlee and closer to Virginia’s coalfields. Brownlee appointed him and fellow assistant U.S. attorney Rick Mountcastle to lead the Purdue investigation, while bringing prosecutors from neighboring jurisdictions into the wider work of the office. The two were described as career government lawyers, not courtroom performers. They did not carry a podium or volunteer to speak to the press; the case would be made through records, legal analysis, and sustained labor rather than public spectacle.

That working style was rooted in an office already accustomed to opioid-related prosecutions. Since OxyContin’s introduction, Ramseyer and Mountcastle’s small Abingdon office had successfully prosecuted ten doctors, pharmacists, and dentists for overprescribing drugs, including prescriptions given to nine-year-old children. They had also sent pill-mill doctors to prison, including one who dispensed prescriptions from the back seat of his car. Those cases placed the Purdue investigation within a changing caseload: the consequences of OxyContin were already appearing in the federal courtroom before the company itself became the target.

Building the Purdue Case

The investigation gathered force over years. Nine state and federal agencies would help the prosecutors build the case over a five-year period. Meanwhile, Brownlee’s office secretly logged millions of records on spreadsheets; employees issued four or five reports a week, and one staff member was assigned solely to catalog documents. Ramseyer and Mountcastle worked within that accumulation of detail, testing how the company’s own material could support a criminal charge.

The legal theory differed from the civil lawsuits that had preceded the prosecution. The government needed to prove that Purdue had misbranded the drug, a broad and technical offense covering such conduct as mislabeling a medicine, fraudulently promoting it, or marketing it for an unapproved use. It did not have to prove that the company’s conduct had directly caused the addiction, misuse, or overdoses associated with OxyContin. The distinction mattered: the prosecutors could pursue the alleged crime in the company’s promotion without having to establish a causal chain from a particular marketing act to an individual’s harm.

Ramseyer later described the work without dramatizing it. In an interview almost a decade after the investigation, he said, “Sometimes people get intimidated by big companies and high-dollar lawyers. You just have to avoid that.” He followed it with an account of the method: “It’s not rocket science; it’s just hard work.” The plainness of those remarks matched the case’s form. Its force accumulated through document review and persistence, against a company that had expected a comparatively modest regional office to be an unthreatening opponent.

The Plea and Corporate Responsibility

At the plea proceedings, Ramseyer emphasized the unusual nature of holding pharmaceutical corporate officers criminally liable in such a case. By accepting the plea, Howard Udell, Michael Friedman, and Paul Goldenheim conceded that they had not been “powerless to prevent the crime.” As corporate officers, Ramseyer argued, they had a duty to ensure that misbranding did not occur. The point was not merely that Purdue had been convicted: the officers’ positions carried obligations, and their acceptance of the plea acknowledged that they could not treat the company’s criminal conduct as beyond their responsibility.

The defense continued to dispute the meaning of that accountability. Lawyers for Friedman cited Purdue’s antidiversion brochures, antifraud prescription pads, law-enforcement liaison unit, local policing support, and later changes to sales-representative compensation. They argued that Friedman had not personally committed a criminal act. In court, the company’s side also repeated that “the enormous benefits of OxyContin far outweigh its risks, even taking into account the grief from those we’ve heard about today.” Ramseyer anticipated that public messaging would seek to reduce the significance of the plea. He predicted, “They will attempt to minimize the crimes to which they pled guilty.” The lawyers did so, the book observes, making the conflict over the meaning of the agreement continue beyond the formal admission of guilt.

Ramseyer later recalled that the three executives seemed distressed throughout the proceedings. “They were very unhappy,” he said, comparing their demeanor with that of people sentenced to decades in prison. His observation did not erase the disparity between their circumstances and the losses described in court; instead, it registered his own surprise at how visibly the executives experienced the proceeding. The case’s significance, in his remarks, lay partly in making corporate responsibility legible in a setting where corporate officers had rarely faced criminal liability of this kind.

Personal Cost and Continuing Questions

The case coincided with Ramseyer’s cancer diagnosis. He had to take a break from the investigation for treatment, and the experience remained fixed in his memory as both a personal ordeal and a professional high point. He hoped the prosecution would have a chilling effect on pharmaceutical companies and doctors who overprescribed medication, but he did not claim certainty that it had done so.

The figures and examples he encountered afterward complicated any easy sense of victory. Ramseyer had read that, in 2010, enough opioid painkillers had been prescribed to medicate every American adult around the clock for a month. When asked about the problem in 2016, he said, “And it’s worse now.” The scale was visible even in the odd commercial afterlife of opioid prescribing: Super Bowl advertisements promoted remedies for opioid-caused constipation, while Purdue had also marketed Senokot, a laxative. Subpoenaed sales-representative notes showed OxyContin and Senokot routinely recommended together. Ramseyer’s wry remark, “So they got you on both ends!” turned a sales detail into a compact illustration of how thoroughly the consequences and commercial responses to opioid use had become entangled.

Narrative Role and Significance

Ramseyer’s role is defined less by personal display than by the prosecution’s contrast between appearance and substance. The company and its lawyers faced prosecutors working from a small regional office; the investigation depended on a painstaking archive rather than a dramatic public campaign. His understated language presents federal prosecution as disciplined work, while his cancer treatment reveals the human cost incurred alongside it. The case could establish criminal misbranding without proving that the conduct caused each individual injury, and Ramseyer hoped its precedent would deter future misconduct without knowing whether it would. His story therefore closes neither with a claim that one plea ended the crisis nor with a claim that prosecution was meaningless: it records a substantial legal achievement beside the continuing scale of opioid prescribing and harm.